KDR and neoplasm: Altiratinib (a novel balanced inhibitor of MET/TIE2/VEGFR2) combined with bevacizumab reduced tumor volume, invasiveness, factor VIII-positive MVD, and Tie2+F4/80+ macrophage infiltration more effectively than bevacizumab alone [238].